The Bethesda Handbook of Clinical Hematology

DESCRIPTION:

 

 

Written by national recognized experts and senior fellows at leading research institutions, including the National Institutes of Health, and edited by Drs. Griffin P. Rodgers and Neal S. Young, The Bethesda Handbook of Clinical Hematology, 5th Edition, is a concise, comprehensive handbook designed for everyday clinical use. Organized in a quick-reference, portable format, it covers the clinical information you need to know for the diagnosis and treatment all of blood and bone marrow disorders. Readable and practical, the Bethesda Handbook features numerous tables, algorithms, illustrations, and bulleted lists throughout to help bridge the gap between cutting-edge science and everyday clinical practice.

 

Provides clinically focused, authoritative, and current guidance in this complex area, logically organized by disease category

Discusses the pathophysiology, natural history, risk factors, diagnosis, management, and follow-up of common hematological diseases

Features new diagnostic and treatment strategies, updated references, and revised information throughout

An ideal resource for practitioners at every level of training: students, residents, and fellows on a hematology or oncology service, as well as internists, hospitalists, family practitioners, pediatricians, and nurse practitioners whose practice includes patients with blood diseases

 

 

TABLE OF CONTENTS:

 

 

 

Chapter 1 ■ Iron Deficiency

 

Absolute versus Functional Iron Deficiency

Iron Metabolism

Absolute Iron Deficiency

Functional Iron Deficiency

Genetics and Iron Deficiency

Treatment of Iron Deficiency Anemia

Dietary Iron

Oral Iron Therapy

Intravenous Iron Therapy

Red Blood Cell Transfusion

Response to Iron Therapy

Treatment of Functional Iron Deficiency

Treatment of Anemia in Patients With Advanced Malignancy

Treatment of Anemia Associated With Chronic Inflammatory Diseases

Chapter 2 ■ Deficiencies of Vitamin B12 and Folate

Vitamin Requirements, Sources, and Stores

Metabolic Roles of Folate and Vitamin B12

Development of Vitamin B12 Deficiency

Development of Folic Acid Deficiency

Patient Populations at Risk

Clinical Presentation

Laboratory Evaluation

Hematologic Abnormalities

Serum Vitamin Concentrations

Serum Methylmalonic Acid and Homocysteine

Therapeutic Trial

Determining the Cause of VITAMIN B12 or Folate Deficiency

Treatment/Response

Chapter 3 ■ Hemolytic Anemia

Etiology and Differential Diagnosis

Clinical Recognition of Hemolytic Anemias

Laboratory Approach to Patients With Suspected Hemolysis

Acute Intravascular Hemolysis

Immune-Mediated Hemolysis

Membranopathies

Cytoskeleton Defects

Membrane defects involving RBC hydration

Neuroacanthocytosis

Enzymopathies

Enzymopathies of Emden-Meyerhof pathway

Enzymopathies of the HMP shunt and glutathione metabolism

Enzymes in the Nucleotide Salvation Pathway

Hemoglobinopathies

Paroxysmal Nocturnal Hemoglobinuria

Special Considerations in Hemolytic Anemia Management

Aplastic Crisis

Treatment Considerations

Secondary complications

Chapter 4 ■ Sickle Cell Anemia and Thalassemia

Pathophysiology

Thalassemias

Hemoglobinopathies: Hemoglobin Structural Variants

Sickle Cell Disease

Other Hemoglobinopathies (E, C, Lepore, D, OArab, Constant Spring)

Diagnosis and Screening

α-Thalassemia Trait and Disease

β-Thalassemia Trait and Major

Sickle Cell Trait and Disease

Clinical Syndromes and Treatment of Sickle Cell Disease

Vaso-occlusive Episodes (Pain Crises)

Infections

Central Nervous System and Eye Disease

Eye Disease

Cardiovascular Manifestations

Pulmonary Complications

Gall Bladder, Hepatic, and Splenic Manifestations

Renal Abnormalities

Priapism

Skeletal Complications and Leg Ulcers

Therapy

Transfusions

HbF Induction

Other Drugs

Special Topics

Contraception and Pregnancy

Anesthesia and Surgery

Sickle Cell Trait

Clinical Syndromes and Treatment of Thalassemia

Transfusions and Splenomegaly

Iron Overload, Thalassemia-Related Complications, and Chelation

Medication Treatment

Therapy With Curative Intent

Hematopoietic Stem Cell Transplantation

Gene Therapy

Chapter 5 ■ Porphyrias

Epidemiology

Pathophysiology

Classification and Clinical Manifestations

Diagnosis

Specific Types of Porphyrias

X-Linked Dominant Protoporphyria

δ-Aminolevulinic Acid Dehydratase Deficiency Porphyria

Acute Intermittent Porphyria

Congenital Erythropoietic Porphyria

Porphyria Cutanea Tarda

Hepatoerythropoietic Porphyria

Hereditary Coproporphyria

Variegate Porphyria

Erythropoietic Protoporphyria

Chapter 6 ■ Bone Marrow Failure Syndromes: Aplastic Anemia, Acquired and Constitutional; Paroxysmal Nocturnal Hemoglobinuria; Pure Red Blood Cell Aplasia; and Agranulocytosis

Acquired Bone Marrow Failure Syndromes

Immune Aplastic Anemia

Etiology and Pathophysiology

Clinical Features

Diagnosis and Differential Diagnosis

Definitive Treatments

Paroxysmal Nocturnal Hemoglobinuria

Etiology and Pathophysiology

Clinical Features

Diagnosis

Treatment

Pure Red Cell Aplasia

Etiology and Pathophysiology

Clinical Features and Diagnosis

Treatment

Large Granular Lymphocytic Leukemia

Etiology and Pathophysiology

Diagnosis and Treatment

Agranulocytosis

Etiology and Pathophysiology

Diagnosis and Treatment

Constitutional Bone Marrow Failure Syndromes

Fanconi Anemia

Clinical Features

Diagnostic Tests

Hematologic Presentations and Cancer Predisposition

Stem Cell Transplantation and Supportive Care

Androgens

Hematopoietic Growth Factors

Telomere Biology Disorders

Diagnostic Testing for Aplastic Anemia With Short Telomeres

GATA2 Haploinsufficiency

Marrow Failure Involving a Single Lineage

Diamond-Blackfan Anemia

Shwachman-Diamond Syndrome

Severe Congenital Neutropenia and Cyclic Neutropenia

Congenital Amegakaryocytic Thrombocytopenia

Chapter 7 ■ Myelodysplastic Syndromes

Etiology

Clonality and Molecular Features

Clinical Features

Diagnostic Studies and Morphologic Classification

Prognostic Criteria and Clinically Relevant Subtypes

Standard Treatments

Supportive Care

Intensive Chemotherapy

Hematopoietic Stem Cell Transplantation

Disease-Modifying Hypomethylating Agents (DNA Methyltransferase Inhibitors)

Immunomodulatory Agents and Immunosuppression

Luspatercept (REBLOZYL)

Investigational Treatments

Chapter 8 ■ The Myeloproliferative Neoplasms: Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis, and Chronic Myelomonocytic Leukemia

Polycythemia Vera

Epidemiology

Pathophysiology

Clinical Features

Diagnostic Criteria

Staging and Prognostic Features

Treatment

Essential Thrombocytosis

Epidemiology

Pathophysiology

Clinical Features

Diagnostic Testing

Treatment

Primary Myelofibrosis

Epidemiology

Pathophysiology

Clinical Features

Diagnostic Testing

Staging and Prognostic Features

Treatment

Chronic Myelomonocytic Leukemia

Epidemiology

Pathophysiology

Clinical Features

Diagnostic Testing

Staging and Prognostic Features

Treatment

Chapter 9 ■ Neutrophil Disorders and Neutropenias

Neutrophil Disorders

Leukocyte Adhesion Deficiency (Disorder in Neutrophil Chemotaxis)

Myeloperoxidase Deficiency

Chronic Granulomatous Disease

Chédiak-Higashi Syndrome (Disorder in Neutrophil Ingestion)

Specific Granule Deficiency

Neutropenias

Acquired Neutropenias

Congenital Neutropenias

Other Inherited Disorders Associated With Clinically Significant Neutropenia

Other Neutropenias

Chapter 10 ■ Childhood Hematologic Diseases

Introduction

Anemia

Microcytic Anemias

Normocytic Anemias

Macrocytic Anemias

Bleeding

Acquired Coagulation Disorders

Inherited Factor Deficiencies

Platelet Disorders

Thrombosis

Congenital Prothrombotic Disorders

Acquired Prothrombotic Disorders

Neutropenia

Leukocytosis

Hematologic Manifestations of Systemic Conditions

Transfusion Support

Specialized Blood Products to Prevent Toxicities

Chapter 11 ■ Acute Myeloid Leukemia

Epidemiology

Etiology

Pathogenesis

Clinical Features

Laboratory Findings

Classification

Diagnostic Evaluation

Prognostic Factors

Treatment

Initial Management

Induction Therapy in Younger Patients Fit for Intensive Chemotherapy

Postremission Treatment in Younger Patients Fit for Intensive Chemotherapy

Hematopoietic Stem Cell Transplantation

Risk-Based Approach to Acute Myeloid Leukemia Treatment in Younger Patients Fit for Intensive Chemotherapy

Induction Therapy for Older Patients or Patients Who Cannot Receive Intensive Chemotherapy

Postremission Treatment in Older Patients or Patients Unsuited for Intensive Chemotherapy

Treatment of Acute Promyelocytic Leukemia

Treatment of Relapsed and Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia in Pregnancy

Evaluation of Measurable Residual Disease

Novel Therapeutic Targets in Acute Myeloid Leukemia

Chapter 12 ■ Acute Lymphoblastic Leukemia

Introduction

Epidemiology

Etiology and Risk Factors

Clinical Features

Laboratory Features

Classification

Prognostic Factors

Treatment

Dose Modification

New Treatment Approaches

Management of Relapse

Allogeneic Stem Cell Transplantation

Supportive Care

Antiemetics

Tumor Lysis Syndrome

Transfusions

Infection Prophylaxis

Chemotherapy Prophylaxis

Nutritional Support

Psychosocial Support

Evaluations

Evaluations during Treatment

Evaluations after Treatment

Late Effects

Chapter 13 ■ Chronic Myelogenous Leukemia

Epidemiology

Pathophysiology

Leukemic Hematopoiesis Originates in a Multipotent Stem Cell

Clonal Dominance

Molecular Basis of CML in the BCR::ABL1 Translocation

Genomic Instability

Presentation

Classic Presentation

Typical Presentation in the Developed World

Rare Presentations

Diagnosis

Blood Count

Blood Film

Bone Marrow

Chromosome Analysis

Molecular Diagnosis

Differential Diagnosis

Course of CML

Chronic Phase

Accelerated Phase

Blastic Phase

Prognostic Factors

Treatment

Treating Newly Diagnosed CML in Chronic Phase

Allogeneic SCT: Treatment With Curative Intent

Treatment of Accelerated Phase

Treatment of Blastic Phase

Special Issues in CML Management

Treatment of Relapse After Transplantation

Leukostasis

Splenic Infarcts

Myelofibrosis

Chloromas

CML in Pregnancy and Parenting

Psychological Response of Patients With CML

Evolving Standard of Care

Choice of TKIs as First-Line Treatment, Generics, and Safety Profile

Trigger to Change TKIs

Lower Doses of TKIs—Dasatinib and Ponatinib

Newer TKIs and Novel Agents

COVID-19 in CML Patients

Chapter 14 ■ Chronic Lymphocytic Leukemia

Background

Etiology and Pathogenesis

Clinical Manifestations

Diagnosis, Imaging, and Laboratory Studies

Complete Blood Count and Blood Smear

Immunophenotyping and Flow Cytometry

Other Laboratory Evaluations

Bone Marrow Biopsy

Lymph Node Biopsy

Computed Tomography and Positron Emission Tomography

Differential Diagnosis

Natural History, Staging, and Prognosis

Immunoglobulin Variable Region Heavy-Chain Gene Mutation

BCR stereotypy

Cytogenetics

Somatic Mutations

ZAP-70 and CD38

CD49d

Lymphocyte Doubling Time

Combination Prognostic Models

Treatment

The Paradigm of Watchful Waiting

Assessing Response to Therapy

Therapeutic Agents

Chemoimmunotherapy

Cellular Therapies

Small Molecules

Unique Aspects of Targeted Agents in Chronic Lymphocytic Leukemia

Individualized Therapy and Predictive Biomarkers

Novel Agents in Development

Complications of Chronic Lymphocytic Leukemia and Their Treatment

Autoimmune Manifestations

Infections

Richter Transformation

Select Internet Resources

Chapter 15 ■ Hodgkin Lymphoma

Introduction

Epidemiology and Risk Factors

Pathology

Classical Hodgkin Lymphoma

Nodular Lymphocyte–Predominant Hodgkin Lymphoma/Nodular Lymphocyte–Predominant B-Cell Lymphoma

Pathogenesis of Classical Hodgkin lymphoma

Transformation of Germinal Center B-Cell into HRS Cells

Tumor Microenvironment and Immune Evasion

Clinical Features

Classical Hodgkin Lymphoma

Nodular Lymphocyte–Predominant Hodgkin Lymphoma/Nodular Lymphocyte–Predominant B-Cell Lymphoma

PreTreatment Evaluation and Staging

Laboratory Tests

Radiologic Studies

Other

Prognosis

Prognostic Factors for Early-Stage Disease

Prognostic Factors for Advanced-Stage Disease

Total Metabolic Tumor Volume

Frontline Management of Classical Hodgkin Lymphoma

Frontline Management of Early-Stage Disease

Chemotherapy Alone Versus Combined Modality Approaches

Response-Adapted Approach for Early-Stage cHL

Frontline Management for Advanced-Stage Disease

Brentuximab Vedotin Incorporated Into Frontline Therapy

Role of Radiation

Response-Adapted Approaches for Advanced-Stage Disease

Management of Relapsed or Refractory cHL

Treatment Options for Relapsed Disease After ASCT

Frontline Management of NLPHL

Early-Stage NLPHL

Advanced-Stage NLPHL

Treatment of Older Patients

Survivorship and Long-Term Follow-up

Follow-up and Screening Recommendations

Conclusions

Acknowledgments

Chapter 16 ■ Non-Hodgkin Lymphomas

Introduction

Epidemiology

Pathophysiology

Classification

Precursor B- and T-Cell Neoplasms

Mature B-Cell Neoplasms

Burkitt Lymphoma

High-Grade B-Cell Lymphoma, With MYC and BCL2 Rearrangements and High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements

Mature T- and NK-Cell Neoplasms

Hodgkin Lymphoma

Immunodeficiency-Associated Lymphoproliferative Disorders

Clinical Management

Staging

Posttherapy Restaging for Response Evaluation

Prognostic Features

Treatment Principles

Principles of Therapy: Indolent B-Cell and T-Cell Lymphomas

Principles of Therapy: Aggressive B-Cell Lymphomas

Mantle Cell Lymphoma

Diffuse Large B-Cell Lymphoma

Treatment Principles: Highly Aggressive B-Cell Lymphoma

Burkitt Lymphoma/B-Cell ALL

Treatment of Recurrent and Refractory B-Cell Lymphoma

Principles of Salvage Therapy

Acquired Immune Deficiency Syndrome–Related Lymphoma (Systemic) Treatment Considerations

T-Cell Lymphoma: Treatment Principles

Chapter 17 ■ Multiple Myeloma

Epidemiology

Diagnostic Criteria of Multiple Myeloma and Related Plasma Cell Disorders

Multiple Myeloma

Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma

Multiple Myeloma

Pathophysiology and Genomics

Initial Evaluation

Staging

Response Criteria

Approach to Newly Diagnosed Multiple Myeloma

Lenalidomide

Bortezomib

Daratumumab

Transplantation

Maintenance

Approach to Relapsed/Refractory MM

Next-Generation IMiDs and Cereblon Modulators (CelMods)

Next-Generation Proteasome Inhibitors

Monoclonal Antibodies

Other Therapeutics

CAR T-Cell and Bispecific Antibody Therapies

Chapter 18 ■ Hematopoietic Stem Cell Transplantation

Autologous Hematopoietic Stem Cell Transplantation

General Considerations

Results of Autologous Hematopoietic Stem Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation

Major Transplant Trends in the United States

Indications for Allogeneic Hematopoietic Stem Cell Transplantation

Antileukemic Potential of Allogeneic Hematopoietic Stem Cell Transplantation: Underlying Principles

Planning Allogeneic Hematopoietic Stem Cell Transplantation

Results of Allogeneic Hematopoietic Stem Cell Transplantation

Complications of Allogeneic Hematopoietic Stem Cell Transplantation

Infectious Complications

Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation

Alternative Donor Transplantation

Chapter 19 ■ Thrombocytopenia

Platelet Biology

Etiology and Clinical Features of Thrombocytopenia

Disorders Characterized by Decreased Production of Platelets

Bone Marrow Failure

Myelodysplasia

Marrow Infiltration

Irradiation and Chemotherapy

Cyclic Thrombocytopenia

Nutritional Deficiencies

Disorders Characterized by Increased Clearance of Platelets

Immune Thrombocytopenia

Heparin-Induced Thrombocytopenia

Thrombotic Microangiopathies

Disseminated Intravascular Coagulation

Posttransfusion Purpura

Neonatal Alloimmune Thrombocytopenia

Von Willebrand Disease, Type 2B

Extracorporeal Circulation-Related Thrombocytopenia

Disorders Characterized by Increased Sequestration of Platelets

Other Causes of Thrombocytopenia

Pseudothrombocytopenia

Mild Persistent Thrombocytopenia

Drug-Induced Thrombocytopenia

Gestational Thrombocytopenia

HIV-Related Thrombocytopenia

Infection- and Sepsis-Related Thrombocytopenia

Hemophagocytosis

Qualitative Platelet Disorders

Wiskott-Aldrich Syndrome

Chapter 20 ■ Disorders of Hemostasis I: Coagulation

The Coagulation System

Coagulation Factors: Background

The Coagulation Cascade

Common Coagulation Tests

Specialized Coagulation Tests

Differential Diagnosis of Abnormal Coagulation Tests

Conditions Associated With a Prolonged aPTT

Conditions Associated With a Prolonged PT

Conditions Associated With Prolonged aPTT and PT

Conditions Associated With Bleeding and Normal Coagulation Tests

Chapter 21 ■ Disorders of Hemostasis II

Disseminated Intravascular Coagulation

Pathophysiology

Presentation

Diagnosis

Treatment

Von Willebrand Disease

Epidemiology

Pathophysiology and Classification

Presentation

Diagnosis

Treatment

Pregnancy and von Willebrand Disease

Qualitative Platelet Disorders

Introduction

Review of Hemostasis and the Role of Platelet Biochemistry

Platelet Function Testing

Acquired Disorders

Inherited Disorders

Chapter 22 ■ Venous Thromboembolism

Deep Venous Thrombosis and Pulmonary Embolism

Diagnosis of Venous Thromboembolism

Utility of d-Dimer

Deep Venous Thrombosis Diagnosis

Pulmonary Embolism Diagnosis

Deep Venous Thrombosis in Sites Other than the Distal Veins of the Lower Extremities

Acquired Thrombophilic States

Heparin-Induced Thrombocytopenia

Nephrotic Syndrome

Antiphospholipid Antibody Syndrome

Paroxysmal Nocturnal Hemoglobinuria

Surgery as a Risk for Acquired Thrombosis

Myeloproliferative Neoplasm

COVID-19 Coagulopathy

Inherited Hypercoagulable States

Activated Protein C Resistance (Factor V Leiden)

Prothrombin Mutation (G20210A)

Deficiencies of Proteins S and C and Antithrombin (Antithrombin III)

Hyperhomocysteinemia

Treatment

Initial Treatment for Acute Venous Thromboembolism

Extended Treatment to Prevent Recurrent Venous Thromboembolism

Inferior Vena Cava Filters in the Treatment of Deep Venous Thrombosis or Pulmonary Embolus

Fibrinolytic Therapy

Chapter 23 ■ Consultations in Anticoagulation

Prophylaxis and Treatment of Venous Thromboembolism in the Patient With Cancer in Specific Clinical Settings

Primary Prophylaxis in Cancer Patients Undergoing Surgical Intervention

Primary Venous Thromboembolism Prophylaxis in Cancer Patients Receiving Chemotherapy, Hormonal, and/or Antiangiogenic Treatment

Primary Prophylaxis in Cancer Patients Who Are Immobilized/Hospitalized

Primary Prophylaxis in Patients With Brain Metastases and Primary Brain Tumors

Treatment of Venous Thromboembolism in Patients With Primary Brain Tumors or Brain Metastases

Treatment of Patients With Trousseau Syndrome

General Approach in Treating Venous Thromboembolism in Cancer Patients

Anticoagulation Options in Cancer Patients With Thrombocytopenia

Thrombosis and Venous Access Devices

Indications for Inferior Vena Cava Filters

Prevention, Diagnosis, and Treatment of Venous Thromboembolism in Pregnancy

Diagnosis of Venous Thromboembolism During Pregnancy

Management of Pregnant Women at an Increased Risk of Venous Thromboembolism

Recognition of Postthrombotic (“Postphlebitic”) Syndrome

Recommendations for Management of Postthrombotic Syndrome

Pharmacologic Approach to Postthrombotic Syndrome

Surgical Management of Postthrombotic Syndrome

Anticoagulation in patients with chronic kidney disease (CKD)

Anticoagulation in patients with obesity and post-bariatric surgery

Antiphospholipid Syndrome

Chapter 24 ■ Blood Transfusion

Blood Cell Antigens

Laboratory Determination of Major Blood Groups

Antiglobulin Test

Blood Compatibility

ABO Incompatibility in Transplant Settings

Minor Incompatibility

Major Incompatibility

Rh Incompatibility

Blood Components and Derivatives

Blood Components and Transfusion Therapy

Whole Blood

Red Blood Cells

Platelets

Platelet Refractoriness

Granulocytes

Fresh Frozen Plasma

Cryoprecipitate

Hematopoietic Stem and Progenitor Cells

Blood Derivatives

Prothrombin Complex Concentrate

Rh Immune Globulin

Derivative and Recombinant Coagulation Factors

Transfusion Reactions and Adverse Sequelae

Acute Hemolytic Transfusion Reaction

Hemolysis Associated With Passive Antibody Infusion

Sickle Cell Hemolytic Transfusion Syndrome

Delayed Hemolytic Transfusion Reaction

Other Causes of Hemolysis

Anaphylactic Transfusion Reactions

Transfusion-Related Acute Lung Injury

Transfusion-Associated Circulatory Overload

Transfusion-Associated Graft Versus Host Disease

Bacterial Contamination and Sepsis

Mild Allergic/Urticarial Transfusion Reactions

Posttransfusion Purpura

Hypotension Associated With Transfusion

Febrile Nonhemolytic Transfusion Reaction

Hemosiderosis

Transfusion-Transmitted Infections

Alternatives to Allogeneic Blood Transfusion

Massive Transfusion

Disseminated Intravascular Coagulation

Immunohematologic Disorders

Hemolytic Disease of the Newborn

Neonatal Alloimmune Thrombocytopenia and Maternal Immune Thrombocytopenic Purpura

Autoimmune Hemolytic Anemias

Therapeutic Apheresis in the Management of Immunohematologic Disorders

Photopheresis (Extracorporeal Photochemotherapy)

Thrombotic Microangiopathies

Dysproteinemias

Chapter 25 ■ Hemochromatosis

Epidemiology and Genetics

Genetic Basis for Classic Hemochromatosis: HFE Mutations

Pathophysiology

Hepcidin: Key Regulator of Iron Homeostasis

Iron Overload Disorders and Hepcidin Deficiency

Role of HFE in the Molecular Mechanism of Hepcidin Regulation

Mechanism of Iron-Mediated Tissue Damage

Clinical Features And Diagnosis of HFE-Hemochromatosis

Diagnostic Definition

Common Clinical Presentation

Laboratory Testing

Risk of Advanced Liver Disease and Role of Liver Biopsy

Indications for Liver Biopsy

Histologic Findings on Liver Biopsy

Radiographic Tests

Population Screening

Laboratory Screening

Screening of Family Members of p.C282Y Homozygotes

Treatment

Phlebotomy Therapy

Guidelines for Therapeutic Phlebotomy

Evaluation of Anemia During Phlebotomy Therapy

Use of Iron Chelators

Arthritis, Endocrine Replacement, Vaccinations, and Cancer Surveillance

Dietary and Lifestyle Counseling

Prognosis and Response to Therapy

Hemochromatosis Subjects As Blood Donors

Non-HFE Iron Overload

Future Challenges

Chapter 26 ■ Consultative Hematology

Hematologic Complications of Pregnancy

Anemia in Pregnancy

Sickle Cell Disease in Pregnancy

Thrombocytopenia in Pregnancy

Microangiopathic Hemolytic Anemia (MAHA)

Immune-Mediated Fetal and Neonatal Cytopenia due to Maternal Fetal Antigen Mismatch

Venous Thromboembolism in Pregnancy

Hematological Manifestations of Tropical Disease

Malaria

Clonal Eosinophilic Disorders

T-Cell Clonal Disorders

Acute Leukemias

Myeloid/Lymphoid Neoplasms Associated With Eosinophilia

Idiopathic Hypereosinophilic Syndrome

Familial HES

Neutropenia

Intrinsic Disorders

Extrinsic Disorders

Neutropenia Due to Large Granular Lymphocyte Syndrome

Neutropenia Associated With Infectious Diseases

Chapter 27 ■ Interpretation of Standard Hematologic Tests

Cellular Analysis of the Peripheral Blood and Bone Marrow

Complete Blood Count

Peripheral Blood Film

Bone Marrow Aspirate/Biopsy

Serum Tests to Evaluate Nutritional and Hypoproliferative Anemias

Serum Iron and Total Binding Capacity Assays

Soluble Transferrin Receptor

Serum Ferritin

Serum Vitamin B12 (Cobalamin)

Serum Methylmalonic Acid

Serum Homocysteine

Serum Intrinsic Factor Antibody Assay

Serum and Red Cell Folate Assays

Serum Erythropoietin

Tests for the Evaluation of Abnormal Hemoglobins and Hemolytic Anemias

Hemoglobin Electrophoresis

High-Performance Liquid Chromatography and Isoelectric Focusing

Sickle Solubility Test

Hb A2 Quantitation

Hb F Quantitation and Hb F Cells

Tests for Unstable Hemoglobins

Glucose-6-Phosphate Dehydrogenase

Serum Haptoglobin

Urine Hemosiderin

Hemostasis and Coagulation Assays

Automated Coagulation Analyzers

Activated Partial Thromboplastin Time

Anti-Xa Assay

Prothrombin Time

Thrombin Time

Specific Factor Assays

Fibrinogen

D-Dimers

Tests of Platelet Function

Tests for Hypercoagulability

Tests for Hyperfibrinolysis

Tests for Evaluation of Patients With Hematologic Malignancies

Serum Protein Electrophoresis

Urine Protein Electrophoresis

Immunofixation

Serum Free Light Chains

Quantitative Serum Immunoglobulins

Serum Cryoglobulins

Serum Viscosity

Serum β2-Microglobulin

Serum Lactate Dehydrogenase

Serum Uric Acid

Molecular Methods

Chapter 28 ■ Basic Principles and Clinical Applications of Flow Cytometry

Introduction

Data Presentation and Interpretation

Applications of Flow Cytometry in Nonmalignant Hematologic Disorders

Applications of Flow Cytometry in Hematologic Malignancies

Index

 

 

An aparitie	13 feb 2024
Autor	GRIFFIN RODGERS, NEAL S. YOUNG
Dimensiuni	152 x 229 mm
Editura	LWW
Format	Paperback
ISBN	9781975211837
Limba	Engleza
Nr pag	560
Versiune digitala	DA